A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy
Latest Information Update: 20 Mar 2025
At a glance
- Drugs Imetelstat (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms IMpress
- Sponsors Geron Corporation
Most Recent Events
- 14 Mar 2025 Planned primary completion date changed from 1 Feb 2025 to 30 Sep 2025.
- 08 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 28 Aug 2024 Status changed from active, no longer recruiting to recruiting.